Silvaco To Present at the 28th Annual Needham Growth Conference

Silvaco To Present at the 28th Annual Needham Growth Conference GlobeNewswire January 05, 2026 SANTA CLARA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Company”, “Silvaco”), a provider of TCAD, EDA software, and SIP solutions that enable innovative semiconductor design and digital twin modeling through AI software and innovation, will participate […]

Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg

PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.1025 per Share

PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.1025 per Share GlobeNewswire January 05, 2026 MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) declares its monthly distribution for January 2026 of $0.1025 per share, payable on February 2, 2026 to stockholders of record as of January

Concrete Pumping Holdings Sets Fourth Quarter and Fiscal Year 2025 Earnings Conference Call for Tuesday, January 13, 2026

Concrete Pumping Holdings Sets Fourth Quarter and Fiscal Year 2025 Earnings Conference Call for Tuesday, January 13, 2026 GlobeNewswire January 05, 2026 DENVER, Jan. 05, 2026 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (“CPH” or the “Company”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., will

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire January 05, 2026 CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 197,900 shares

TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred Shares

TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred Shares GlobeNewswire January 05, 2026 ATHENS, Greece, Jan. 05, 2026 (GLOBE NEWSWIRE) — TEN Ltd. (NYSE: TEN) (“TEN” or the “Company”), a leading diversified crude, product and LNG tanker operator, today announced that its Board of Directors declared the regular quarterly cash dividend

Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support

Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support GlobeNewswire January 05, 2026 New York City, Jan. 05, 2026 (GLOBE NEWSWIRE) — January 5, 2026 Citrus Burn is a citrus-derived dietary supplement formulated to support metabolism, daily energy levels, and thermogenic activity through plant-based ingredients. As interest in natural

Evolution Metals & Technologies Corp. Consummates Business Combination Prior to Trading on NASDAQ

(NasdaqGM:EMAT), West Palm Beach, FL, Jan. 05, 2026 (GLOBE NEWSWIRE) — Evolution Metals & Technologies Corp. (“EM&T” or the “Company”), a company focused on building a secure, reliable, and vertically integrated global supply chain for critical minerals and materials (“CMM”), including battery and magnet materials, through a closed-loop integrating recycling model, midstream processing, and advanced

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

(NASDAQ:CRNX), SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.0 million of shares of its

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire January 05, 2026 SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell,

Scroll to Top